Drug Trial Radar · NCT07654114
Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 21, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Connecta Therapeutics, S.L.Industry
- Sponsor type
- Industry
- Collaborators
- Hospital del Mar Research Institute (IMIM); Corporacion Parc Tauli; Ministry of Science and Innovation, Spain; Astrum CRO, S.L.
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome.
Conditions
- Fragile X Syndrome (FXS)
- Fragile X Syndrome
Interventions
CTH120Drug
15 participants will be randomized to receive CTH120 75 mg hard capsules. Capsules of CTH120 will be administered by the oral route to participants twice a day, one capsule in the morning and one capsule in the evening, at approximately the same times each day, after breakfast (morning dose) and after dinner (evening dose), with a glass of water. The evening dose will be taken approximately 12 h from the morning dose, and preferably before midnight. The evening dose must not be taken before at least 8 hours from the morning dose.
CTH120 placebo hard capsulesOther
15 participants will be randomized to receive CTH120 placebo hard capsules. Capsules of CTH120 matching placebo will be administered by the oral route to participants twice a day, one capsule in the morning and one capsule in the evening, at approximately the same times each day, after breakfast (morning dose) and after dinner (evening dose), with a glass of water. The evening dose will be taken approximately 12 h from the morning dose, and preferably before midnight. The evening dose must not be taken before at least 8 hours from the morning dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs).Time frame: From Day 1 to End-of-study: EOS will be on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in blood pressure (mmHg).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in pulse rate (bpm).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in body temperature (ºC).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: heart rate (bpm).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: rhythm.Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: PQ/PR interval (ms).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QRS duration (ms).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QT (ms).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in electrocardiogram (ECG) values: QTcF (ms).Time frame: From Day 1 to End-of-study (EOS): on Day 56 (±2 days).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: haematology.Time frame: Screening visit (From Day -28 to Day -1), on Day 15, on Day 28, on Day 42 and Day 56 (± 2 days) (End-of-study (EOS)).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: serum chemistry.Time frame: Screening visit (From Day -28 to Day -1), on Day 15, on Day 28, on Day 42 and Day 56 (± 2 days) (End-of-study (EOS)).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: coagulation.Time frame: Screening visit (From Day -28 to Day -1), on Day 15, on Day 28, on Day 42 and Day 56 (± 2 days) (End-of-study (EOS)).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: urinalysis.Time frame: Screening visit (from Day -28 to Day -1).
- Treatment-emergent potentially clinically significant abnormalities (PSCAs) in safety laboratory parameters: viral serology and detection.Time frame: Screening visit (from day -28 to Day -1).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital del Mar Medical Research Institute
Barcelona, Barcelona, Spain · Recruiting
Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT)
Sabadell, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.